SK CDM-QIP Diabetes Flow Sheet

Туре о	of Diabetes: \Box Type 1 \Box Type 2 \Box	Patient Name:						
Date D	Diagnosed/Duration of DM:	Date of Birth:						
Como	rbidities: Hypertension Dyslipide							
□ OSA □ Mental Health Condition □ CKD stage □ Other								
		Date:	Date:		Date:			
Subje	ctive							
	A1c (target ≤ 7% or)	Result Test Date	Result	Test Date	Result Test Date			
	Glycemic Therapy/Medications							
	dividentic inerapy/wedications							
ent	Adherence/concerns							
em	Paritary altrease manufa							
nag	Review glucose records							
Ma								
Glycemic Management	Hypoglycemic episodes							
lyce	Consider frequency, severity; provide educational resources							
B	DM and driving discussed							
	SGI medical reporting form if using insulin							
	Contraception/preconception advice for women							
	Sick day management reviewed							
	Consider SADMANS, other patient handouts							
1	Is patient experiencing low	☐ Yes ☐ No ☐ Not asked	☐ Yes	☐ No ☐ Not asked	☐ Yes ☐ No ☐ Not asked			
ocia	mood/anhedonia/anxiety? (Consider use of PHQ-9, GAD-7, diabetes distress scales)							
hos	Comments							
Psychosocial review								
<u> </u>	Nutrition/Diet review							
	Nutrition/ Diet review							
Lifestyle	Physical activity							
	(Reduce sedentary time, aerobic plus resistance exercise)							
	Smoking status	☐ Non-smoker ☐ Ex-smoker ☐ Smoker	☐ Non-		☐ Non-smoker ☐ Ex-smoker ☐ Smoker			
	Smoking cessation advice (if required)	☐ Yes ☐ No	☐ Yes	□ No	☐ Yes ☐ No			
CVD Screen	Any CAD/PAD/HF/AF symptoms							
	(angina/MI symptoms may be absent; consider exertional dyspnea, change in exercise tolerance, HF symptoms,							
	claudication, palpitations)							
	ECG	☐ Ordered today		red today	☐ Ordered today			
	(Baseline at age 40 or DM >15 years; repeat q3-5 years, more often if CVD symptoms)	☐ Up to date☐ Not indicated	☐ Up to	o date ndicated	☐ Up to date☐ Not indicated			
		ot malcatea	_ 1001		vot maicatea			





SK CDM-QIP Diabetes Flow Sheet

		Date:	Date:	Date:
Lipids	Lipid profile – LDL, non-HDL (Primary target: LDL < 2.0 mmol/L or >50% reduction with treatment; non-HDL < 2.6 mmol/L)	Result Test Date LDL	Result Test Date LDL	Result Test Date LDL
		Non-HDL	Non-HDL	Non-HDL
Nephropathy	Urine ACR (normal < 2 mg/mmol) (not required if eGFR < 15 mL/min)	Result Test Date	Result Test Date	Result Test Date
	Serum creatinine	Result Test Date	Result Test Date	Result Test Date
	eGFR (normal > 60ml/min)	Result Test Date	Result Test Date	Result Test Date
	Nephropathy (Abnormal ACR, eGFR on ≥ 2 tests in 3 months)	☐ Yes ☐ No	☐ Yes ☐ No	□ Yes □ No
thy	Dilated eye exam (type 1 annually, type 2 q1-2 years)			
obs	Retinopathy	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
Retinopathy	Severity/comments			
Neuropathy	Symptoms (Paresthesia/pain/numbness, GI symptoms, ED, diabetic foot complications)			
Neu	Diabetic foot exam done today Record details in exam section	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
	Peripheral neuropathy	☐ Yes ☐ No	☐ Yes ☐ No	☐ Yes ☐ No
	Weight (kg)			
Physical exam	BP (target 130/80)			
	Diabetic foot exam			
	Other exam findings			
CVD medications	Statin (Recommended to reduce CVD risk in adults with DM1 or DM2 with any of the following features: clinical CVD, age 240 years, age >30 years and duration of DM >15 years, microvascular complications, presence of other CV risk factors in accordance with Lipid CPG.)	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No - indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No - indicated, declined ☐ No - unable to afford	Indicated: Continue Start No - not appropriate No - not tolerated No - indicated, declined No - unable to afford
	ACEI/ARB (Recommended to reduce CV risk in adults with DM1 or DM2 with any of the following: clinical CVD, age ≥55 years with an additional CV risk factor or end organ damage (albuminuria, retinopathy, LVH), microvascular complications)	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No - indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No - indicated, declined ☐ No - unable to afford	Indicated: ☐ Continue ☐ Start ☐ No - not appropriate ☐ No - not tolerated ☐ No - indicated, declined ☐ No - unable to afford
	Antiplatelet agent (if established CVD, not for primary prevention)	☐ Not indicated ☐ Yes	☐ Not indicated ☐ Yes	☐ Not indicated ☐ Yes
	CV medication adherence Other comments/notes			





SK CDM-QIP Diabetes Flow Sheet

		Date:	Date:	Date:
Vaccines	Vaccines reviewed Details/comments (Check EHR viewer for vaccine status)			
Management Plan	Patient goals/self-management			
	Advance care planning (Discuss as needed; provide resources)			
	Referrals for education/nutrition/exercise			
	Referrals to medical specialists			
	Assessment and management plan (Changes to medications, resources provided to patient, etc.)			

For CDM QIP online resources/handouts, information points for aspects of care, and details of CDM QIP indicators – https://www.ehealthsask.ca/services/CDM/Pages/default.aspx





